A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study

Keywords

• Humans
• *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology
• *Lung Neoplasms/drug therapy/pathology
• *Antibodies, Monoclonal, Humanized/administration & dosage/therapeutic use
• *Antineoplastic Combined Chemotherapy Protocols/therapeutic use
• *Antibodies, Monoclonal/administration & dosage/therapeutic use
• *B7-H1 Antigen/metabolism/antagonists & inhibitors
• Male
• Female
• Treatment Outcome
• Clinical trial
• Cytotoxic T-lymphocyte-associated antigen 4
• Immune checkpoint inhibitor
• Immunotherapy
• Programmed cell death ligand-1